These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9473784)
1. Report on the 4th Central European Lung Cancer Conference, September 26-29, 1996, Gdańsk, Poland. Dziadziuszko R Neoplasma; 1997; 44(4):275-6. PubMed ID: 9473784 [No Abstract] [Full Text] [Related]
2. Report on the 4th Central European Lung Cancer Conference Gdansk, Poland, 26-29 September 1996. Senkus-Konefka E Lung Cancer; 1997 Mar; 16(2-3):259-62. PubMed ID: 9152956 [No Abstract] [Full Text] [Related]
3. [A report from the IV Inter-European Conference on the subject of lung neoplasms in Gdańsk, 26-29 September 1996]. Madrzak J Pneumonol Alergol Pol; 1997; 65(1-2):134-5. PubMed ID: 9289296 [No Abstract] [Full Text] [Related]
4. Abstracts of the 9th Central European Lung Cancer Conference. Gdansk, Poland, September 23-25, 2004. Lung Cancer; 2004 Sep; 45 Suppl 3():S1-92. PubMed ID: 15505910 [No Abstract] [Full Text] [Related]
5. KRAS mutation spectrum notably diverges between non-small cell lung and colorectal carcinomas. Compagnone M; Chetaille B; Olschwang S J Thorac Oncol; 2012 Apr; 7(4):773-4; author reply 774. PubMed ID: 22425934 [No Abstract] [Full Text] [Related]
6. Views and news from Melbourne, the Sixth World Conference on Lung Cancer. The EORTC Lung Cancer Co-operative Group. Giaccone G; van Zandwijk N Eur Respir J; 1992 Sep; 5(8):1023-6. PubMed ID: 1426194 [No Abstract] [Full Text] [Related]
8. Orosomucoïd: prealbumin ratio in the monitoring of lung cancer. Charet JC; Watine J; Lepretre A; Raimbault C; Charet P Clin Biochem; 1996 Jun; 29(3):287-90. PubMed ID: 8740518 [No Abstract] [Full Text] [Related]
9. Non-small cell lung cancer: report on the 5th central European lung cancer conference. Zatloukal P Biomed Pharmacother; 1999 Apr; 53(3):154-62. PubMed ID: 10349505 [TBL] [Abstract][Full Text] [Related]
10. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590 [TBL] [Abstract][Full Text] [Related]
11. Consensus statement on a screening programme for the detection of early lung cancer in Poland. Rzyman W; Didkowska J; Dziedzic R; Grodzki T; Orłowski T; Szurowska E; Langfort R; Biernat W; Kowalski D; Dyszkiewicz W; Jędrzejczyk T; Zdrojewski T; Nawrocki S; Jassem E; Adamek M Adv Respir Med; 2018; 86(1):53-74. PubMed ID: 29490422 [TBL] [Abstract][Full Text] [Related]
12. [Current capabilities and procedures for diagnosing lung neoplasms]. Ochmański W Przegl Lek; 1997; 54(2):126-34. PubMed ID: 9198823 [TBL] [Abstract][Full Text] [Related]
13. [Commentary to the diagnostic and therapeutic recommendations of Polish Lung Cancer Group (see page 88)]. Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):1. PubMed ID: 17541905 [No Abstract] [Full Text] [Related]
14. [Is a delay in diagnosis and treatment of lung cancer still a problem?]. Góralczyk J; Buchwald J; Drózdz W; Harazda M; Kołodziejczyk E; Krynicka E; Laczyńska E; Lukasiewicz M; Mackowska I; Młodkowski J Pol Tyg Lek; 1985 Apr 8-15; 40(14-15):403-6. PubMed ID: 4011487 [No Abstract] [Full Text] [Related]
15. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Felip E; Concha Á; de Castro J; Gómez-Román J; Garrido P; Ramírez J; Isla D; Sanz J; Paz-Ares L; López-Ríos F Clin Transl Oncol; 2015 Feb; 17(2):103-12. PubMed ID: 25351175 [TBL] [Abstract][Full Text] [Related]
16. [I. History of Immunotherapy and Cancer Vaccine for Lung Cancer]. Suzuki H; Takagi H; Owada Y; Watanabe Y; Inoue T; Fukuhara M; Yamaura T; Muto S; Okabe N; Hasegawa T; Shio Y Gan To Kagaku Ryoho; 2017 Aug; 44(8):646-649. PubMed ID: 28860434 [No Abstract] [Full Text] [Related]
17. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy]. Kayser G Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246 [TBL] [Abstract][Full Text] [Related]
18. Serum mass profile signature as a biomarker of early lung cancer. Widlak P; Pietrowska M; Polanska J; Marczyk M; Ros-Mazurczyk M; Dziadziuszko R; Jassem J; Rzyman W Lung Cancer; 2016 Sep; 99():46-52. PubMed ID: 27565913 [TBL] [Abstract][Full Text] [Related]
19. [Study of CEA as a marker of cancer and its surrounding tissue in 145 cases of lung carcinoma]. Jia XS Zhonghua Bing Li Xue Za Zhi; 1988 Sep; 17(3):173-5. PubMed ID: 2852548 [No Abstract] [Full Text] [Related]
20. [Personalized therapy in non-small cell lung cancer: from diagnosis to therapy]. Moldvay J Orv Hetil; 2012 Jun; 153(23):909-16. PubMed ID: 22668592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]